PT-141 regulatory status in 2026: what is actually approved
One molecule, two regulatory identities — branded and compounded.
TL;DR
- PT-141 (bremelanotide) is FDA-approved as Vyleesi for one specific indication in premenopausal women.
- Compounded PT-141 is dispensed by state-licensed 503A pharmacies and is not itself FDA-approved.
- PT-141 is not on the FDA Category 2 restricted list, which means access through a licensed clinician is clearer than for several other peptides in 2026.
How it works
Think of a drug's regulatory identity like a building permit. The molecule bremelanotide has one approved permit — Vyleesi, for premenopausal women with HSDD (hypoactive sexual desire disorder — persistent low desire that causes distress). That permit was issued by the FDA in 2019 (Vyleesi label, FDA, 2019). The same molecule, prepared by a compounding pharmacy as a custom dose, is operating under a different rule book — the 503A pharmacy framework — with state board of pharmacy oversight (FDA compounding Q&A, 2024). Same building. Different permits. Different oversight.
What it is
PT-141 is a melanocortin receptor agonist (in plain English: a molecule that switches on a specific brain receptor involved in sexual desire). Its branded form, Vyleesi, is FDA-approved for one defined condition. Compounded PT-141 is the same active molecule prepared by a 503A pharmacy. The compounded version is not itself FDA-approved. That single sentence is what most people are searching for when they look up the regulatory status.
Who asks about it
People come to this question after seeing PT-141 mentioned on a podcast, in a clinic ad, or in a friend's protocol. They want a clear answer: is this legal, is the FDA on board, and what does a clinician actually prescribe. Many have been told contradictory things online. The honest answer is short and worth giving plainly.
What the research says
The Vyleesi approval was based on the RECONNECT trial program, which studied bremelanotide in premenopausal women with acquired HSDD. The active ingredient has additional published research in male sexual dysfunction and obesity-linked melanocortin biology, but those uses are not FDA-approved indications. Compounded PT-141 access is supported under FDA compounding policy when there is a documented patient-specific need a clinician identifies — the standard 503A framework. Studied for its effects on sexual desire and arousal. Off-label prescribing by a licensed clinician is legal in many states under standard medical practice rules.
What to know before considering it
PT-141 access requires a licensed clinician. Common reported side effects include nausea (about 4 in 10 people in the Vyleesi trials), headache, and flushing — usually peaking 1 to 2 hours after the injection. Generally well-tolerated in physician-supervised protocols. Contraindications include uncontrolled high blood pressure and known cardiovascular disease. Individual response varies.
The Halftime POV
PT-141 has one of the cleanest regulatory pictures in our category: an FDA-approved version for one indication, a compounded version for clinician-directed off-label use, and no Category 2 restriction. We give people the picture, name the indication, and point them to a licensed clinician. We do not oversell the molecule. We tell them what is actually approved and what is not.
Related reading:
- PT-141 (bremelanotide): how melanocortin signaling affects desire
- Bremelanotide is FDA-approved for women: what Vyleesi actually treats
- Category 1 vs Category 2 peptides
FAQ
Q: Is PT-141 FDA-approved? A: The active ingredient bremelanotide is FDA-approved as Vyleesi for one specific indication: acquired, generalized hypoactive sexual desire disorder in premenopausal women. Compounded PT-141 preparations are not themselves FDA-approved.
Q: Is compounded PT-141 legal? A: Compounded PT-141 is dispensed by state-licensed 503A pharmacies with a valid prescription from a licensed clinician. The compounded preparation is not FDA-approved. Access rules vary by state.
Q: Can men use PT-141? A: Vyleesi is FDA-approved for premenopausal women only. Off-label prescribing by a licensed clinician is legal in many states. Off-label use is at clinician discretion based on the published literature.
Q: Is PT-141 a Category 2 peptide? A: No. PT-141 is not on the FDA Category 2 list. It can be compounded by 503A pharmacies. This is one of the few intimacy-related peptides with a clear access path in 2026.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
Is PT-141 FDA-approved?
The active ingredient bremelanotide is FDA-approved as Vyleesi for one specific indication: acquired, generalized hypoactive sexual desire disorder in premenopausal women. Compounded PT-141 preparations are not themselves FDA-approved.
Is compounded PT-141 legal?
Compounded PT-141 is dispensed by state-licensed 503A pharmacies with a valid prescription from a licensed clinician. The compounded preparation is not FDA-approved. Access rules vary by state.
Can men use PT-141?
Vyleesi is FDA-approved for premenopausal women only. Off-label prescribing by a licensed clinician is legal in many states. Off-label use is at clinician discretion based on the published literature.
Is PT-141 a Category 2 peptide?
No. PT-141 is not on the FDA Category 2 list. It can be compounded by 503A pharmacies. This is one of the few intimacy-related peptides with a clear access path in 2026.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.